Log in to search using one of your social media accounts:

 

Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval
Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the  U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to treat a broader range of patients. The FDA approved the Boulder-based company (Nasdaq: CLVS) selling rucaparib as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tu be, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. The FDA completed its… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 6, 2018 Category: American Health Authors: Greg Avery Source Type: news

Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval
Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the  U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to an expanded range of patients. The FDA approved the Boulder-based company (Nasdaq: CLVS) selling rucaparib as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. That means more women with… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 6, 2018 Category: Biotechnology Authors: Greg Avery Source Type: news

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
The fine line between human health and disease can be driven by the interplay between host and microbial factors. This "metagenome" regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, a...
Source: ScienceNOW - March 22, 2018 Category: Science Authors: Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., Gajewski, T. F. Tags: Immunology special/review Source Type: news

Blood Test Could Make Monitoring Mesothelioma Easier
A simple blood test may have the potential to replace the more costly and burdensome CT scan for monitoring post-treatment recurrence and progression of pleural mesothelioma. Researchers at the University of Bristol in the United Kingdom recently found that the changing levels of the protein mesothelin in blood often mirrored CT scan results in patients who already had completed treatment. BMC Cancer published results of their study — a first of its kind — which included the long-term monitoring of 41 patients with mesothelioma who had either completed chemotherapy or other supportive care. “With this stu...
Source: Asbestos and Mesothelioma News - March 8, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Convergence of Wnt, growth factor, and heterotrimeric G protein signals on the guanine nucleotide exchange factor Daple
Cellular proliferation, differentiation, and morphogenesis are shaped by multiple signaling cascades, and their dysregulation plays an integral role in cancer progression. Three cascades that contribute to oncogenic potential are those mediated by Wnt proteins and the receptor Frizzled (FZD), growth factor receptor tyrosine kinases (RTKs), and heterotrimeric G proteins and associated GPCRs. Daple is a guanine nucleotide exchange factor (GEF) for the G protein Gαi. Daple also binds to FZD and the Wnt/FZD mediator Dishevelled (Dvl), and it enhances β-catenin–independent Wnt signaling in response to Wnt5a-FZD...
Source: Signal Transduction Knowledge Environment - February 27, 2018 Category: Science Authors: Aznar, N., Ear, J., Dunkel, Y., Sun, N., Satterfield, K., He, F., Kalogriopoulos, N. A., Lopez-Sanchez, I., Ghassemian, M., Sahoo, D., Kufareva, I., Ghosh, P. Tags: STKE Research Articles Source Type: news

New Clinical Trial Focuses on Immunotoxins and Mesothelioma
An exciting new mesothelioma clinical trial will study one approach for improving how well immunotoxin drugs work. The phase I trial is enrolling peritoneal and pleural mesothelioma patients. Immunotoxins, which are targeted therapies, attach to and destroy cancer cells. This approach already has shown promise in a small clinical trial. This new clinical trial will give mesothelioma patients an immunotoxin in combination with another substance to suppress the immune system. The goal of the National Cancer Institute (NCI) clinical trial is to learn how safe and tolerable the combination of the immunotoxin and immune suppre...
Source: Asbestos and Mesothelioma News - February 26, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasis
The incidence of melanoma is increasing, particularly in young women, and the disease remains incurable for many because of its aggressive, metastatic nature and its high rate of resistance to conventional, targeted, and immunological agents. Cathepsins are proteases that are critical for melanoma progression and therapeutic resistance. Intracellular cathepsins cleave or degrade proteins that restrict cancer progression, whereas extracellular cathepsins directly cleave the extracellular matrix and activate proinvasive proteases in the tumor microenvironment. Cathepsin secretion is markedly increased in cancer cells. We inv...
Source: Signal Transduction Knowledge Environment - February 20, 2018 Category: Science Authors: Tripathi, R., Fiore, L. S., Richards, D. L., Yang, Y., Liu, J., Wang, C., Plattner, R. Tags: STKE Research Articles Source Type: news

Structural basis for the interaction between the cell polarity proteins Par3 and Par6
Polarity is a fundamental property of most cell types. The Par protein complex is a major driving force in generating asymmetrically localized protein networks and consists of atypical protein kinase C (aPKC), Par3, and Par6. Dysfunction of this complex causes developmental abnormalities and diseases such as cancer. We identified a PDZ domain–binding motif in Par6 that was essential for its interaction with Par3 in vitro and for Par3-mediated membrane localization of Par6 in cultured cells. In fly embryos, we observed that the PDZ domain–binding motif was functionally redundant with the PDZ domain in targeting ...
Source: Signal Transduction Knowledge Environment - February 13, 2018 Category: Science Authors: Renschler, F. A., Bruekner, S. R., Salomon, P. L., Mukherjee, A., Kullmann, L., Schütz-Stoffregen, M. C., Henzler, C., Pawson, T., Krahn, M. P., Wiesner, S. Tags: STKE Research Articles Source Type: news

SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors
Mutations mimicking growth factor–induced proliferation and motility characterize aggressive subtypes of mammary tumors. To unravel currently unknown players in these processes, we performed phosphoproteomic analysis on untransformed mammary epithelial cells (MCF10A) that were stimulated in culture with epidermal growth factor (EGF). We identified ladinin-1 (LAD1), a largely uncharacterized protein to date, as a phosphorylation-regulated mediator of the EGF-to-ERK pathway. Further experiments revealed that LAD1 mediated the proliferation and migration of mammary cells. LAD1 was transcriptionally induced, phosphorylat...
Source: Signal Transduction Knowledge Environment - January 30, 2018 Category: Science Authors: Roth, L., Srivastava, S., Lindzen, M., Sas-Chen, A., Sheffer, M., Lauriola, M., Enuka, Y., Noronha, A., Mancini, M., Lavi, S., Tarcic, G., Pines, G., Nevo, N., Heyman, O., Ziv, T., Rueda, O. M., Gnocchi, D., Pikarski, E., Admon, A., Caldas, C., Yarden, Y. Tags: STKE Research Articles Source Type: news

KIF22 coordinates CAR and EGFR dynamics to promote cancer cell proliferation
The coxsackievirus and adenovirus receptor (CAR) is a transmembrane receptor that plays a key role in cell-cell adhesion. CAR is found in normal epithelial cells and is increased in abundance in various human tumors, including lung carcinomas. We investigated the potential mechanisms by which CAR contributes to cancer cell growth and found that depletion of CAR in human lung cancer cells reduced anchorage-independent growth, epidermal growth factor (EGF)–dependent proliferation, and tumor growth in vivo. EGF induced the phosphorylation of CAR and its subsequent relocalization to cell junctions through the activation ...
Source: Signal Transduction Knowledge Environment - January 30, 2018 Category: Science Authors: Pike, R., Ortiz-Zapater, E., Lumicisi, B., Santis, G., Parsons, M. Tags: STKE Research Articles Source Type: news

Neoadjuvant Chemotherapy Tied to Better Survival in Advanced Ovarian Cancer Neoadjuvant Chemotherapy Tied to Better Survival in Advanced Ovarian Cancer
The adoption of neoadjuvant chemotherapy is associated with reduced mortality in women with advanced epithelial ovarian cancer, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition. Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer. Fecal microbiota transplantation (FMT) from cancer patients who responded to ICIs into germ-free or antibiotic-treated mice ameliorated the antitumor effects of PD-1 blockade, whereas FMT from nonresponding patients failed to do so. Metagenomics of patient stool samples at diagnosis revealed correlati...
Source: ScienceNOW - January 4, 2018 Category: Science Authors: Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillere, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., Fidelle, M., Flament, C., Poirier-Colame, V., Opolon, P., Klein, C., Iribarren, K., Mondragon, L., Jacquelot, Tags: Immunology, Medicine, Diseases reports Source Type: news

Electron microscope images reveal how cells absorb a vital mineral
(Columbia University Medical Center) Columbia University Medical Center (CUMC) researchers have obtained the first detailed snapshots of the structure of a membrane pore that enables epithelial cells to absorb calcium. The findings could accelerate the development of drugs to correct abnormalities in calcium uptake, which have been linked to cancers of the breast, endometrium, prostate, and colon. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2017 Category: Cancer & Oncology Source Type: news

Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT
The precursor homocysteine is metabolized either through the methionine cycle to produce methionine or through the transsulfuration pathway to synthesize cysteine. Alternatively, cysteine can be obtained through uptake of its oxidized form, cystine. Many cancer cells exhibit methionine dependency such that their proliferation is impaired in growth media in which methionine is replaced by homocysteine. We showed that oncogenic PIK3CA and decreased expression of SLC7A11, a gene that encodes a cystine transporter also known as xCT, correlated with increased methionine dependency in breast cancer cells. Oncogenic PIK3CA was su...
Source: Signal Transduction Knowledge Environment - December 19, 2017 Category: Science Authors: Lien, E. C., Ghisolfi, L., Geck, R. C., Asara, J. M., Toker, A. Tags: STKE Research Articles Source Type: news

Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients. The Boulder-based company (Nasdaq: CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. The FDA says it will make a decision by April 6, 2018,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 6, 2017 Category: Pharmaceuticals Authors: Greg Avery Source Type: news

Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients. The Boulder-based company (Nasdaq: CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. The FDA says it will make a decision by April 6, 2018,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 6, 2017 Category: Biotechnology Authors: Greg Avery Source Type: news

Invasive cells in head and neck tumors predict cancer spread
(Massachusetts Eye and Ear Infirmary) Head and neck tumors that contain cells undergoing a partial epithelial-to-mesenchymal transition --   which transforms them from neatly organized blocks into irregular structures that extrude into the surrounding environment -- are more likely to invade and spread to other parts of the body, according to a new study led by researchers from Mass. Eye and Ear, Massachusetts General Hospital (MGH) and the Broad Institute of MIT and Harvard. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2017 Category: Cancer & Oncology Source Type: news

Gut microbiome influences efficacy of PD-1based immunotherapy against epithelial tumors
This piece of research is behind the headline: Gut bacteria " boost " cancer therapy. This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies).The findings are of interest, but don't have any immediate implications for c...
Source: Current Awareness Service for Health (CASH) - November 17, 2017 Category: Consumer Health News Source Type: news

Computer program finds new uses for old drugs
(Case Western Reserve University) Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy. In a recent study published in Oncogene, the researchers successfully translated DrugPredict results into the laboratory, and showed common pain medications--like aspirin--can kill patient-derived epithelial ovarian cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 16, 2017 Category: Cancer & Oncology Source Type: news

Cancer treatment response may be affected by gut bacteria
Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of part...
Source: NHS News Feed - November 3, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Surveillance safe for non-cancerous breast lesion typically treated surgically
(American College of Surgeons) The detection of certain non-cancerous 'high risk' breast lesions can lead to surgical treatment in women, but one of the largest studies of a specific type of high-risk lesion, flat epithelial atypia, calls for close observation, rather than surgical removal of these lesions in most cases, according to study results published on the website of the Journal of the American College of Surgeons in advance of print. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 31, 2017 Category: Cancer & Oncology Source Type: news

Papers of note in Nature 550 (7677)
This week’s articles highlight inflammatory memory in epithelial stem cells; ubiquitin-specific protease inhibitors that target cancer cells; the identification of a sphingosine 1-phosphate exporter; and G protein signaling hotspots on the plasma membrane. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - October 31, 2017 Category: Science Authors: VanHook, A. M. Tags: STKE Editors ' Choice Source Type: news

Study finds N-alpha-acetyltransferase D (NatD) promotes lung cancer progression
(Nanjing University School of Life Sciences) Researchers at Nanjing University and their collaborators have found that NatD, which mediates N-alpha-terminal acetylation (Nt-acetylation) of histone H4, promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate the transcription factor Slug, a key regulator of the epithelial-to-mesenchymal transition (EMT). Their study results are published in the Oct. 13, 2017, issue of the journal Nature Communications. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 13, 2017 Category: Biology Source Type: news

Aggressive Mesothelioma Surgery Benefits More Patients
Patients diagnosed with the worst cases of pleural mesothelioma could benefit the most from the aggressive surgery they often are denied, according to one recent study. The findings have raised questions about the restrictive surgery selection process at many specialty centers handling mesothelioma, the rare and aggressive cancer caused by asbestos exposure. “In some cases, patients are not being offered the aggressive surgery that could help their quality of life,” lead author Dr. Wickii Vigneswaran, mesothelioma specialist and chief of thoracic surgery at the Loyola University Medical Center, told Asbestos.co...
Source: Asbestos and Mesothelioma News - October 11, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Aggressive Mesothelioma Surgery asbestos exposure Dr. Wickii Vigneswaran epithelial mesothelioma epithelioid histology extrapleural pneumonectomy Loyola mesothelioma program Loyola University Medical Center mesothelioma Chicago mesotheli Source Type: news

Qiagen Partners with Cell Diagnostics Company
ANGLE plc, a liquid biopsy company, has secured a valuable partnership with molecular testing giant Qiagen and an exclusive option agreement with Queen Mary University of London. ANGLE is known for Parsortix, its novel system for capturing and harvesting circulating tumor cells (CTCs) from blood. A Large Selling Opportunity with Qiagen The co-marketing partnership with Qiagen isn’t just a major win for ANGLE—it will also give Qiagen, which has more than 500,000 customers, an additional opportunity in the liquid biopsy space and the ability to offer ANGLE’s unique CTC harvesting technology alongside its ow...
Source: MDDI - September 19, 2017 Category: Medical Devices Authors: Marie Thibault Tags: IVD Source Type: news

Regulation of autophagy, NF-{kappa}B signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells
KRAS mutant non–small cell lung cancer (NSCLC) may be classified into epithelial or mesenchymal subtypes. Despite having the same "driver" mutation, mesenchymal NSCLCs are less responsive than are epithelial NSCLCs to inhibition of the RAS pathway. Identifying alternative networks that promote survival specifically in mesenchymal NSCLC may lead to more effective treatments for this subtype. Through their numerous targets in cellular signaling pathways, noncoding microRNAs (miRNAs) often function as tumor suppressors or oncogenes. In particular, some miRNAs regulate the epithelial-mesenchymal transition (EMT...
Source: Signal Transduction Knowledge Environment - September 12, 2017 Category: Science Authors: Mehta, A. K., Hua, K., Whipple, W., Nguyen, M.-T., Liu, C.-T., Haybaeck, J., Weidhaas, J., Settleman, J., Singh, A. Tags: STKE Research Articles Source Type: news

Mesothelioma Patients Survive Longer with Trimodal Treatment
Pleural mesothelioma patients who undergo aggressive multimodal treatment live almost twice as long after diagnosis than those who do not, according to a recent extensive study. Researchers at MD Anderson Cancer Center in Texas found a combination of surgery, chemotherapy and radiation extended survival time significantly, regardless of disease histology or cancer stage. “We recommend that all patients with [malignant pleural mesothelioma] be evaluated by multidisciplinary teams that are experienced in the management of mesothelioma for consideration of surgery-based, multimodality treatment,” the authors wrote...
Source: Asbestos and Mesothelioma News - September 5, 2017 Category: Environmental Health Authors: Matt Mauney Tags: biphasic histology Dr. Anne Tsao Dr. Boris Sepesi Dr. Daniel Gomez Dr. David Rice Dr. Mark Berry epithelial mesothelioma Journal of Clinical Oncology md anderson cancer center mesothelioma chemotherapy mesothelioma mortality surgery Source Type: news

New insight into how excess belly fat may increase cancer risk
Conclusion This animal and laboratory study investigated the possible cellular relationship between excess body fat – specifically fat around the body organs – and cancer risk. It seems one key mechanism by which excess visceral fat could stimulate healthy cells to develop into cancerous ones could be through FGF2 levels. The researchers hope their study could pave the way for possible cancer prevention strategies by stopping FGF2 production in obese people with excess belly fat. They even go as far as suggesting that blocking FGF2 receptors could be one part of a treatment approach after a diagnosis of breas...
Source: NHS News Feed - September 1, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer
Androgen deprivation therapy (ADT) targeting the androgen receptor (AR) is a standard therapeutic regimen for treating prostate cancer. However, most tumors progress to metastatic castration-resistant prostate cancer after ADT. We identified the type 1, 2, and 4 collagen–binding protein transforming growth factor–β (TGFβ)–induced protein (TGFBI) as an important factor in the epithelial-to-mesenchymal transition (EMT) and malignant progression of prostate cancer. In prostate cancer cell lines, AR signaling stimulated the activity of the transcription factor SPDEF, which repressed the expression o...
Source: Signal Transduction Knowledge Environment - August 15, 2017 Category: Science Authors: Chen, W.-Y., Tsai, Y.-C., Yeh, H.-L., Suau, F., Jiang, K.-C., Shao, A.-N., Huang, J., Liu, Y.-N. Tags: STKE Research Articles Source Type: news

Cytology versus HPV testing for cervical cancer screening in the general population: a DTA Review from the Cochrane Gynaecological, Neuro-oncology and Orphan Cancers Group, (CGNOC)
Cochrane Reviews are systematic reviews of research in health care and policy. They are internationally recognized as a high-quality source of evidence for decision-making. They collate and summarize all the best available research evidence on the effects of healthcare interventions or the accuracy of diagnostic tests into a systematic review.Diagnostic Test Accuracy Reviews (DTA) provide essential information regarding the accuracy of the available diagnostic tools for key decision makers, including patients, clinicians, guideline developers and researchers.  The purpose of a Cochrane DTA review is very like the purp...
Source: Cochrane News and Events - August 14, 2017 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

Gene editing brings pig organ transplant closer
Conclusion This promising research shows that it can be possible to use gene editing techniques to eliminate retroviruses from pigs, removing one of the potential barriers to using genetically modified pigs as organ donors for humans. There are a few points to note. As the researchers say, though they have shown that pig retroviruses can be passed onto human cells in the laboratory, we don't know what the effects would be in real life. We don't know whether pig retroviruses would be transferred to humans and whether they could cause cancers or immunodeficiency illnesses, for example. The research is at an early stage. The ...
Source: NHS News Feed - August 11, 2017 Category: Consumer Health News Tags: Genetics/stem cells Source Type: news

Gene-regulatory factors shown to improve pancreatic cancer response to chemotherapy
(Tokyo Medical and Dental University) TMDU researchers revealed that, in pancreatic cancer, the microRNAs miR-509-5p and miR-1243 can promote E-cadherin expression and thereby reduce the likelihood of cells undergoing epithelial-mesenchymal transition, or indeed reverse this transition. This ability to stop cells from adopting a phenotype linked to high migration and invasiveness was also shown to synergistically increase the cancer cell-killing efficacy of gemcitabine, which is promising for developing more effective combinatorial treatments for pancreatic cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 1, 2017 Category: Cancer & Oncology Source Type: news

ovarian epithelial fallopian cancer
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 27, 2017 Category: General Medicine Source Type: news

SMART Protocol for Mesothelioma Adds Immunotherapy
In conclusion, we demonstrated the importance of the immune system in the benefit of clinical protocols using…radiation followed by surgery.” The post SMART Protocol for Mesothelioma Adds Immunotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 6, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: emerging treatments for mesothelioma immunotherapy for mesothelioma SMART mesothelioma SMART protocol mesothelioma smart protocol mix with immunotherapy Source Type: news

The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b
Metastasis is a multistep process by which tumor cells disseminate from their primary site and form secondary tumors at a distant site. The pathophysiological course of metastasis is mediated by the dynamic plasticity of cancer cells, which enables them to shift between epithelial and mesenchymal phenotypes through a transcriptionally regulated program termed epithelial-to-mesenchymal transition (EMT) and its reverse process, mesenchymal-to-epithelial transition (MET). Using a mouse model of spontaneous metastatic breast cancer, we investigated the molecular mediators of metastatic competence within a heterogeneous primary...
Source: Signal Transduction Knowledge Environment - June 13, 2017 Category: Science Authors: Zhou, W., Ye, X.-l., Xu, J., Cao, M.-G., Fang, Z.-Y., Li, L.-Y., Guan, G.-H., Liu, Q., Qian, Y.-H., Xie, D. Tags: STKE Research Articles Source Type: news

An elegans solution: Worm genetic screen maps cell-to-cell communication in human cancer
(Medical University of South Carolina) In the May 22, 2017, issue of Developmental Cell, researchers at the Medical University of South Carolina Hollings Cancer Center developed a cross-species genetic screen in worms to follow cell-to-cell communication in human cancer. The genome-wide screen is being used to chart a roadmap between mesodermal cells and epithelial cells in the tumor microenvironment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 22, 2017 Category: Cancer & Oncology Source Type: news

Moffitt Opens Mesothelioma Study for Rare Cancer Subtypes
The Moffitt Cancer Center in Tampa has opened a mesothelioma clinical trial involving an anti-cancer enzyme drug showing unprecedented success with the most difficult disease subtypes. Patients with sarcomatoid and biphasic histology — the most treatment-resistant subtypes of mesothelioma — can now enroll in a phase 2/3 clinical trial involving the effectiveness of ADI-PEG 20 (pegylated arginine deiminase) in combination with standard chemotherapy. Thoracic surgeon Dr. Jacques Fontaine, director of the Mesothelioma Research and Treatment Center at Moffitt, told Asbestos.com that he and fellow investigators are ...
Source: Asbestos and Mesothelioma News - April 25, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: doctor jacques fontaine improving mesothelioma prognosis mesothelioma chemotherapy with cisplatin mesothelioma clinical trial mesothelioma treatments moffitt cancer center Source Type: news

Epithelial Proliferation in Biopsies Tied to Breast Cancer Risk Epithelial Proliferation in Biopsies Tied to Breast Cancer Risk
Women with progressive epithelial proliferation across serial biopsies have an increased risk of breast cancer, while those with regression of initial proliferative disease without atypia face a lower risk compared with no change.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 14, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news

[Report] Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Immunotherapy has clinical activity in certain virally associated cancers. However, the tumor antigens targeted in successful treatments remain poorly defined. We used a personalized immunogenomic approach to elucidate the global landscape of antitumor T cell responses in complete regression of human papillomavirus–associated metastatic cervical cancer after tumor-infiltrating adoptive T cell therapy. Remarkably, immunodominant T cell reactivities were directed against mutated neoantigens or a cancer germline antigen, rather than canonical viral antigens. T cells targeting viral tumor antigens did not display prefere...
Source: ScienceNOW - April 13, 2017 Category: Science Authors: Sanja Stevanovi ć Source Type: news

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Immunotherapy has clinical activity in certain virally associated cancers. However, the tumor antigens targeted in successful treatments remain poorly defined. We used a personalized immunogenomic approach to elucidate the global landscape of antitumor T cell responses in complete regression of human papillomavirus–associated metastatic cervical cancer after tumor-infiltrating adoptive T cell therapy. Remarkably, immunodominant T cell reactivities were directed against mutated neoantigens or a cancer germline antigen, rather than canonical viral antigens. T cells targeting viral tumor antigens did not display prefere...
Source: ScienceNOW - April 13, 2017 Category: Science Authors: Stevanovic, S., Pasetto, A., Helman, S. R., Gartner, J. J., Prickett, T. D., Howie, B., Robins, H. S., Robbins, P. F., Klebanoff, C. A., Rosenberg, S. A., Hinrichs, C. S. Tags: Immunology reports Source Type: news

The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB
Triple-negative breast cancer (TNBC) is particularly aggressive and difficult to treat. For example, the transforming growth factor–β (TGF-β) pathway is implicated in TNBC progression and metastasis, but its opposing role in tumor suppression in healthy tissues and early-stage lesions makes it a challenging target. Therefore, additional molecular characterization of TNBC may lead to improved patient prognosis by informing the development and optimum use of targeted therapies. We found that musculoaponeurotic fibrosarcoma (MAF) oncogene family protein K (MAFK), a member of the small MAF family of transcripti...
Source: Signal Transduction Knowledge Environment - April 11, 2017 Category: Science Authors: Okita, Y., Kimura, M., Xie, R., Chen, C., Shen, L. T.-W., Kojima, Y., Suzuki, H., Muratani, M., Saitoh, M., Semba, K., Heldin, C.-H., Kato, M. Tags: STKE Research Articles Source Type: news

Survival Similar With Debulking by Laparotomy, Laparoscopy
Similar three - year survival rates for women with epithelial ovarian cancer undergoing debulking (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 10, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Surgery, Journal, Source Type: news

FDA Approves Niraparib for Recurrent Ovarian Cancer
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 28, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news

FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers
The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 27, 2017 Category: American Health Source Type: news

Hitting cancer with high-intensity ultrasound, immunotherapy
In a new study, researchers have shown that combining high-intensity focused ultrasound with two immunotherapies (a PD-1 checkpoint inhibitor and TLR9 agonist) can produce excellent response rates in mouse models of epithelial cancer. They also found that, for the combination to be effective, immunotherapies must come first. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 23, 2017 Category: Science Source Type: news

Immunotherapy Motolimod Fails to Improve Survival in Ovarian Cancer
The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial. (Source: CancerNetwork)
Source: CancerNetwork - March 15, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news

Hormonal maintenance therapy may improve survival in women with rare serous carcinoma
For women with a rare subtype of chemo-resistant epithelial ovarian or peritoneum cancer, hormone maintenance therapy may significantly improve survival, according to a new study in theJournal of Clinical Oncology.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 23, 2017 Category: Endocrinology Source Type: news

Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peritoneum cancer
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 22, 2017 Category: Science Source Type: news

Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peri
(University of Texas M. D. Anderson Cancer Center) For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2017 Category: Cancer & Oncology Source Type: news